Nano-X Imaging Ltd. (NASDAQ: NNOX) is making strategic moves to broaden the commercial reach and technological flexibility of its AI-driven medical imaging solutions. The company announced an exclusive three-year reseller agreement with Vertec Scientific to distribute HealthOST, its AI-powered software for spinal CT analysis, in the United Kingdom. The deal includes minimum annual license commitments, establishing a dedicated UK channel for the product. HealthOST provides qualitative and quantitative analysis of spinal CT images, aiding clinicians in evaluating spinal musculoskeletal diseases such as osteoporosis.
Separately, Nanox.AI has optimized its imaging AI framework for Intel Core Ultra processors using OpenVINO, Intel’s open-source toolkit for AI inference. This optimization enables AI inference to run locally on hospital hardware, potentially reducing reliance on cloud connectivity. By processing data on-premise, hospitals could benefit from faster results, improved data privacy, and more flexible deployment options. Together, these developments support Nanox.AI’s strategy of extracting additional clinical value from already performed scans while expanding commercial reach.
The UK agreement with Vertec Scientific is significant because it provides a direct route to market for HealthOST in a country with an aging population and a high prevalence of osteoporosis. According to the International Osteoporosis Foundation, one in three women and one in five men over 50 will experience an osteoporotic fracture. Early detection through AI-assisted analysis of existing CT scans could lead to earlier interventions and better patient outcomes. For investors, the minimum annual license commitments suggest a predictable revenue stream and validate the commercial potential of Nanox.AI’s algorithms.
The Intel optimization addresses a critical barrier to AI adoption in healthcare: the need for reliable, low-latency computing. Many hospitals lack the infrastructure or bandwidth to send large imaging datasets to the cloud for processing. By enabling local inference on Intel Core Ultra processors, Nanox.AI offers a solution that can operate within existing hospital IT environments. This could accelerate adoption among healthcare providers that are cautious about cloud-based solutions due to data security or connectivity concerns.
Nano-X Imaging, through its Nano-X Imaging Ltd. (NASDAQ: NNOX) (“Nanox”) platform, aims to drive the transition to preventive healthcare by combining affordable imaging hardware, AI-based solutions, and cloud-based software. The company’s ecosystem includes Nanox.ARC, Nanox.AI, Nanox.CLOUD, and teleradiology services. For more information, visit www.Nanox.vision. The latest news and updates relating to NNOX are available in the company’s newsroom at https://ibn.fm/NNOX.
These developments are important for the medical imaging industry because they demonstrate how AI can be integrated into existing workflows without requiring major infrastructure changes. They also highlight the growing trend of on-premise AI, which may appeal to hospitals with strict data governance policies. As healthcare systems worldwide face rising costs and increasing demand for diagnostic services, solutions that enhance efficiency and extract more value from existing scans are likely to gain traction.
BioMedWire, a specialized communications platform for the biotech and life sciences sectors, originally reported this news. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides corporate communications solutions and social media distribution. For more details, visit BioMedWire or see the full disclaimer at https://www.BioMedWire.com/Disclaimer.
